Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a

Summary

Inflammation and abnormal amount of lipids in the blood are key factors for the development and progression of atherosclerosis (thickening of the artery wall) and cardiovascular disease. Lipoprotein (a) is a pro-inflammatory plasma lipoprotein that is believed to be a risk factor for cardiovascular diseases. Vascular inflammation generates a range of effects, including endothelial dysfunction and migration of white blood cells into the vessel wall, which results in increased risk of cardiovascular events. This study is designed to assess the effects of multiple monthly intravenous infusions with the fully human antibody called PC-mAb, in subjects with elevated lipoprotein (a).

Timeline

Start

2017-10-11

Primary completion

2018-03-19

Completion

2018-07-03

Outcome

Outcome not reported

Stopped: “Terminated”

Drugs

Indications